Edwards Lifesciences Corporation (EW) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.51B USD | Liabilities, Current |
| Cash and equivalents | 2.91B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 770.40M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.13B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.51B | $2.91B | (m) | $770.40M | $1.13B | (m) |
| 2026-03-31 | (m) | $1.41B | $2.45B | (m) | $775.70M | $1.12B | (m) |
| 2025-12-31 | (m) | $1.81B | $2.94B | (m) | $659.60M | $1.13B | (m) |
| 2025-09-30 | (m) | $1.59B | $2.69B | (m) | $693.30M | $1.14B | (m) |
| 2025-06-30 | (m) | $1.40B | $3.27B | (m) | $697.00M | $1.14B | (m) |
| 2025-03-31 | (m) | $1.39B | $3.14B | (m) | $669.20M | $1.11B | (m) |
| 2024-12-31 | (m) | $1.51B | $3.05B | (m) | $609.10M | $1.09B | (m) |
| 2024-09-30 | (m) | $1.94B | $3.68B | (m) | $716.00M | $1.10B | (m) |
| 2024-06-30 | (m) | $1.22B | $1.64B | (m) | $778.30M | $1.02B | (m) |
| 2024-03-31 | (m) | $1.11B | $1.22B | (m) | $817.60M | $1.21B | (m) |
| 2023-12-31 | (m) | $1.20B | $1.14B | (m) | $775.10M | $1.17B | (m) |
| 2023-09-30 | (m) | $1.24B | $1.41B | (m) | $739.80M | $1.03B | (m) |
| 2023-06-30 | (m) | $1.16B | $1.04B | (m) | $754.40M | $980.20M | (m) |
| 2023-03-31 | (m) | $1.08B | $872.50M | (m) | $717.70M | $914.30M | (m) |
| 2022-12-31 | (m) | $1.02B | $769.00M | (m) | $643.00M | $875.50M | (m) |
| 2022-09-30 | (m) | $917.90M | $1.25B | (m) | $618.10M | $757.80M | (m) |
| 2022-06-30 | (m) | $969.10M | $1.20B | (m) | $636.40M | $740.00M | (m) |
| 2022-03-31 | (m) | $949.90M | $1.03B | (m) | $636.30M | $730.60M | (m) |
| 2021-12-31 | (m) | $1.03B | $862.80M | (m) | $582.20M | $726.70M | (m) |
| 2021-09-30 | (m) | $966.50M | $1.51B | (m) | $600.60M | $737.80M | (m) |
| 2021-06-30 | (m) | $886.20M | $1.31B | (m) | $640.50M | $759.50M | (m) |
| 2021-03-31 | (m) | $799.00M | $1.17B | (m) | $586.60M | $767.90M | (m) |
| 2020-12-31 | (m) | $893.90M | $1.18B | (m) | $514.60M | $802.30M | (m) |
| 2020-09-30 | (m) | $846.30M | $1.02B | (m) | $549.70M | $773.30M | (m) |
| 2020-06-30 | (m) | $873.20M | $903.50M | (m) | (m) | $735.10M | (m) |
| 2020-03-31 | (m) | $746.90M | $662.90M | (m) | (m) | $662.20M | (m) |
| 2019-12-31 | (m) | $902.40M | $1.18B | (m) | $543.60M | $640.90M | (m) |
| 2019-09-30 | (m) | $775.80M | $1.19B | (m) | (m) | $611.10M | (m) |
| 2019-06-30 | (m) | $697.00M | $726.80M | (m) | (m) | $624.90M | (m) |
| 2019-03-31 | (m) | $646.50M | $709.20M | (m) | (m) | $630.90M | (m) |
| 2018-12-31 | (m) | $876.60M | $714.10M | (m) | $456.90M | $607.00M | (m) |
| 2018-09-30 | (m) | $1.26B | $1.26B | (m) | $423.80M | $583.80M | (m) |
| 2018-06-30 | (m) | $1.18B | $1.23B | (m) | $431.40M | $568.10M | (m) |
| 2018-03-31 | (m) | $1.31B | $1.23B | (m) | $406.60M | $573.90M | (m) |
| 2017-12-31 | (m) | $1.40B | $818.30M | (m) | $421.60M | $554.90M | (m) |
| 2017-09-30 | (m) | $735.20M | $630.30M | (m) | (m) | $538.40M | (m) |
| 2017-06-30 | (m) | (m) | $508.20M | (m) | (m) | $491.60M | (m) |
| 2017-03-31 | (m) | (m) | $819.30M | (m) | (m) | $431.40M | (m) |
| 2016-12-31 | (m) | $532.50M | $930.10M | (m) | $365.50M | $396.60M | (m) |
| 2016-09-30 | (m) | (m) | $645.00M | (m) | (m) | $401.00M | (m) |
| 2016-06-30 | (m) | (m) | $369.90M | (m) | (m) | $367.60M | (m) |
| 2016-03-31 | (m) | (m) | $501.40M | (m) | (m) | $356.60M | (m) |
| 2015-12-31 | (m) | $476.20M | $718.40M | (m) | $315.40M | $339.90M | (m) |
| 2015-09-30 | (m) | (m) | $646.10M | (m) | (m) | $333.50M | (m) |
| 2015-06-30 | (m) | (m) | $597.60M | (m) | (m) | $313.30M | (m) |
| 2015-03-31 | (m) | (m) | $457.00M | (m) | (m) | $298.50M | (m) |
| 2014-12-31 | (m) | $434.40M | $653.80M | (m) | $288.00M | $296.80M | (m) |
| 2014-09-30 | (m) | (m) | $404.10M | (m) | (m) | $303.60M | (m) |
| 2014-06-30 | (m) | (m) | $498.60M | (m) | (m) | $317.10M | (m) |
| 2014-03-31 | (m) | (m) | $295.70M | (m) | (m) | $308.00M | (m) |
| 2013-12-31 | (m) | $345.60M | $420.40M | (m) | $302.50M | $308.90M | (m) |
| 2013-09-30 | (m) | (m) | $471.00M | (m) | (m) | $313.90M | (m) |
| 2013-06-30 | (m) | (m) | $372.70M | (m) | (m) | $299.50M | (m) |
| 2013-03-31 | (m) | (m) | $401.50M | (m) | (m) | $288.50M | (m) |
| 2012-12-31 | (m) | $347.40M | $310.90M | (m) | $321.10M | $281.00M | (m) |
| 2012-09-30 | (m) | (m) | $305.80M | (m) | (m) | $286.00M | (m) |
| 2012-06-30 | (m) | (m) | $304.30M | (m) | (m) | $265.40M | (m) |
| 2012-03-31 | (m) | (m) | $213.30M | (m) | (m) | $268.30M | (m) |
| 2011-12-31 | (m) | $335.20M | $171.20M | (m) | $283.80M | $261.30M | (m) |
| 2011-09-30 | (m) | $302.00M | $451.10M | (m) | (m) | $247.90M | (m) |
| 2011-06-30 | (m) | $313.30M | $468.20M | (m) | (m) | $229.40M | (m) |
| 2011-03-31 | (m) | $445.20M | $433.80M | (m) | (m) | $217.70M | (m) |
| 2010-12-31 | (m) | $337.80M | $396.10M | (m) | $277.30M | $203.60M | (m) |
| 2010-09-30 | (m) | $382.20M | $361.00M | (m) | (m) | $212.20M | (m) |
| 2010-06-30 | (m) | (m) | $320.30M | (m) | (m) | $182.30M | (m) |
| 2010-03-31 | (m) | (m) | $321.20M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $334.10M | (m) | (m) | $165.90M | (m) |
| 2009-09-30 | (m) | (m) | $287.60M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $183.10M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $218.70M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $141.80M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |